Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q969R5
UPID:
LMBL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q969R5; Q8TEN1; Q96SC4; Q9BQI2; Q9UGS4
Background:
Lethal(3)malignant brain tumor-like protein 2 is a putative Polycomb group (PcG) protein, involved in maintaining the transcriptionally repressive state of genes through chromatin modification. It binds to monomethylated and dimethylated 'Lys-20' on histone H4 and histone H3 peptides monomethylated or dimethylated on 'Lys-4', 'Lys-9', or 'Lys-27'.
Therapeutic significance:
Understanding the role of Lethal(3)malignant brain tumor-like protein 2 could open doors to potential therapeutic strategies.